Ryan D H, Bickers J N, Vial R H, Hussein K, Bottomley R, Hewlett J S, Wilson H E, Stuckey W J
Cancer Treat Rep. 1980 Aug-Sep;64(8-9):869-72.
The Southwest Oncology Group did a limited institutional pilot study of the combination of doxorubicin and ifosfamide in the treatment of previously treated adult patients with acute leukemia. Thirty-four patients received one or two courses of the combination. All patients had received prior chemotherapy and 32 had received prior anthracycline chemotherapy. Three patients died before their responses could be fully evaluated. Fourteen patients achieved complete remission (41%) and one patient achieved partial remission. The complete remission rate was 27% for patients with acute myeloblastic leukemia (myelomonoblastic leukemia, monoblastic leukemia, and erythroleukemia) and 89% for patients with acute lymphocytic and undifferentiated leukemia (ALL). Toxic effects included severe hematologic reactions in 33 of 34 patients, hematuria in six patients, altered sensorium in one patient, and congestive heart failure in one patient. The safety of the combination was established and toxic side effects of this therapy were tolerable. The 89% complete remission rate for previously treated patients with ALL suggests that the combination of doxorubicin and ifosfamide may be particularly effective in ALL.
西南肿瘤协作组对阿霉素和异环磷酰胺联合治疗既往接受过治疗的成年急性白血病患者进行了一项有限的机构性试点研究。34例患者接受了一个或两个疗程的联合治疗。所有患者均接受过先前的化疗，32例接受过先前的蒽环类化疗。3例患者在其反应能够得到充分评估之前死亡。14例患者获得完全缓解（41%），1例患者获得部分缓解。急性髓细胞白血病（粒单核细胞白血病、单核细胞白血病和红白血病）患者的完全缓解率为27%，急性淋巴细胞白血病和未分化白血病（ALL）患者的完全缓解率为89%。毒性作用包括34例患者中的33例出现严重血液学反应，6例患者出现血尿，1例患者出现意识改变，1例患者出现充血性心力衰竭。该联合治疗的安全性得到确立，且该疗法的毒副作用是可耐受的。既往接受过治疗的ALL患者89%的完全缓解率表明，阿霉素和异环磷酰胺联合治疗可能对ALL特别有效。
